Q1 2021: Good growth in the first quarter
Significant events during the first quarter · Net sales increased by 9% (20% adjusted for currency changes) to SEK 171 m (158). · EBITDA margin was 28% (19%). · First deliveries related to the Pan-European agreement with Perrigo, which includes the launch of Probi's ClinBac™ concept in 14 European countries. · Strategic partnership with the Chinese pharmaceutical company China National Pharmaceutical Foreign Trade Corporation (Sinopharm Foreign Trade) a wholly owned subsidiary of China National Pharmaceutical Group Corporation (Sinopharm) for the launch of three of Probi's